Jing Wu

Jing Wu

Auto-generated profile, based on publicly available information

Jing Wu

Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230000, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JWJing Wu
Jing Wu
ZSZuojun Shen
Zuojun Shen
More and more studies report that exosomes released by various cells can serve as a medium for information exchange between different cells. Through a deep understanding of the physical and chemical properties of exosomes, the researchers revealed a more precise molecular mechanism of its participation in the process of intercellular communication. In particular, microRNA (miRNA) is found inside exosomes, as well as long noncoding RNA (lncRNA). Extensive evidence indicates that exosomal miRNAs participates in the occurrence and development of lung cancer and plays a variety of roles. Therefore, the release of RNA‐containing exosomes in many different kinds of body fluids has caused widespread interest among researchers. In this review, we report evidence from human studies involving miRNAs and other ncRNAs in exosomes associated with lung cancer as diagnostic and prognostic markers. Currently, there is a small amount of evidence that exosomal miRNAs can be used as early diagnosis and prognostic markers for lung cancer, and their exact role in lung cancer patients still needs further study.

18 May 2022 in Cancer Medicine
Verified
Journal Article
Open access
JWJing Wu
Jing Wu
ZFZian Feng
Zian Feng
RWRui Wang
Rui Wang
ALAng Li
Ang Li
HWHong Wang
Hong Wang
ZSZuojun Shen
Zuojun Shen
The aim of this study was to identify miRNAs in plasma exosomes as noninvasive biomarkers for the early diagnosis of lung adenocarcinoma (LUAD). First, exosomal miRNA profiling of three patients with early LUAD and three patients with benign lung disease were screened by next‐generation sequencing (NGS) method. Sequencing results showed that 154 exosomal miRNAs were differentially expressed in the plasma of LUAD patients, among which 68 miRNAs were up‐regulated and 86 miRNAs were down‐regulated. GSE137140 is a GEO database containing serum miRNAs sequencing data from 1566 lung cancer patients and 1774 non‐cancer patients controls. When comparing the sequencing data, it was found that most miRNAs (37/68) up‐regulated in our LUAD group were also significantly up‐regulated in GSE137140, suggesting that circulating miRNAs in lung cancer patients may be enriched in plasma exosomes. In GSE137140, the AUC of the combination of hsa‐miR‐103b, hsa‐miR‐29c‐5p and hsa‐miR‐877‐5p was 0.873, showing great potential as new tumor markers. To our knowledge, these three exosomal miRNAs have not been reported in lung cancer research. Furthermore, bioinformatics tools were used to analyze the target genes of three candidate miRNAs, which were indeed closely related to the occurrence and development of lung cancer. Bioinformatics algorithms deduced a highly conserved sequence in the 3’‐UTR of SFRP4, FOXM1 and TMEM98 that could be bound with miR‐103b/877‐5p/29c‐5p. A luciferase assay indicated that miR‐103b/877‐5p/29c‐5p directly targeted the 3’‐UTR of SFRP4, FOXM1 and TMEM98, respectively. Finally, three candidate miRNAs were validated by qRT‐PCR in 17 early LUAD samples and 17 control plasma samples. Integration of bioinformatics analysis and experimental validation identifies, this study provides novel insights into miRNA‐related networks in LUAD. Hsa‐miR‐103b, hsa‐miR‐29c‐5p, and hsa‐miR‐877‐5p may be used as diagnostic biomarkers for early LUAD.

8 November 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YSYuru Shi
Yuru Shi
JWJing Wu
Jing Wu
TLTing Liu
Ting Liu
YLYue Li
Yue Li
YLYang Liu
Yang Liu
YQYingjie Qi
Yingjie Qi
Purpose: To explore the clinical value of detecting pathogens in pus samples by metagenomic next-generation sequencing (mNGS). Methods: The 25 pus samples from infected patients were collected in this research. The positive rate and consistency of pathogenic bacteria detected by mNGS and conventional methods were compared. The pathogen types detected by the two methods were analyzed. Furthermore, the modifications of antibiotic treatment therapy were also evaluated based on mNGS results. Results: The sensitivity of mNGS method in detecting pathogenic bacteria in pus samples was better than that of conventional method (96% vs 40%; P < 0.01). Only 10 samples were detected pathogens by conventional methods, but 24 samples were detected by mNGS method. In specific, the results of conventional methods showed 10 samples had 11 kinds of pathogenic bacteria, of which 9 samples were single pathogen and 1 sample had two kinds of pathogenic bacteria. The results of mNGS method showed 24 samples were detected with 54 kinds of pathogenic bacteria, of which 15 samples were detected with single pathogen, and 9 samples were detected with two or more kinds of pathogenic bacteria. The two methods had 9(36%) consistent results, 14 (56%) completely different results, and 2 (8%) partially consistent results, and the kappa value was 0.19. Notably, mNGS could detect viruses, anaerobic bacteria, and other uncommon pathogens simultaneously. Conclusion: The application of mNGS in the detection of pus specimens from different parts not only have high accuracy rate and also reduce the turnaround time of diagnosis. In addition, the performance of mNGS detection of anaerobic bacteria and caustic bacteria is better than conventional methods. The mNGS diagnosis in pus sample may play an important role in clinical diagnosis and treatment strategy decisions.

1 June 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
JLJiaxing Liu
Jiaxing Liu
YLYe Li
Ye Li
TLTing Liu
Ting Liu
YSYuru Shi
Yuru Shi
YWYun Wang
Yun Wang
YQYingjie Qi
Yingjie Qi
Background: Mycobacterium tuberculosis (Mtb) survives inside a human host for a long time in the form of latent tuberculosis infection (LTBI). Latent infection of tuberculosis has the opportunity of developing into active tuberculosis (ATB), which has greatly endangered human health. The existing diagnostic methods cannot effectively distinguish LTBI from ATB. Therefore, more effective diagnostic biomarkers and methods are urgently needed. Methods: Here, we screened the GEO data set, conducted joint differential analysis and target gene enrichment analysis, after filtering the disease-related database, we screened the differential miRNA related to TB. The qPCR was used to verify the miRNAs in 84 serum samples. Different combinations of biomarkers were evaluated by logistic regression to obtain a biomarker panel with good performance for diagnosing LTBI. Results: A panel with two miRNAs (hsa-let-7d-5p, hsa-miR-140-5p) was established to differentiate LTBI from ATB. Receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) are 0.930 (sensitivity = 100%, specificity = 88.5%) and 0.923 (sensitivity = 100%, specificity = 92.3%) with the biomarker panel for the training set and test set respectively. Conclusion: The findings indicated that the logistic regression model built by let-7d-5p and miR-140-5p has the ability to distinguish LTBI from active TB patients.

1 March 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
TLTing Liu
Ting Liu
JLJiaxing Liu
Jiaxing Liu
JWJing Wu
Jing Wu
LQLinghan Qin
Linghan Qin
YSYuru Shi
Yuru Shi
YQYingjie Qi
Yingjie Qi
Purpose: Severe Fever with Thrombocytopenia Syndrome (SFTS) is an infectious disease with rapid onset and high case fatality rate. The study was to explore the clinical value by examining the serum level of 25-hydroxyvitamin D (25 (OH) D) in SFTS patients. Methods: One hundred and five patients and 156 healthy controls were included. Univariate and multivariate regression analyses were performed to identify independent risk factors for disease progression. Subject operating characteristics (ROC) curves were drawn, and the corresponding area under the curve (AUC) was calculated to assess the sensitivity and specificity of the diagnostic disease. Results: The 25 (OH) D level of disease group was lower than that of healthy control group (22.12 (18.43, 25.86) ng/mL vs 27.36 (23.20, 32.71) ng/mL; P< 0.05). The 25 (OH) D level of severe disease group was lower than that of mild disease group (20.55(16.30, 24.44) ng/mL vs 24.94(20.89, 31.91) ng/mL; P< 0.05). And there was no significant difference of 25 (OH) D level between the survival group and death group in severe disease group. Multivariate Logistic regression analysis showed that the 25 (OH) D level under 19.665 ng/mL was an independent risk factor for the development of SFTS (OR = 0.901, P=0.040). Furthermore, age more than 68.5 years old and lactate dehydrogenase (LDH) more than 1023.5U/L were independent risk factors for death in severe patients with SFTS. Conclusion: Patients with SFTS have reduced 25 (OH) D level, and 25 (OH) D is a risk factor for disease severity in patients with SFTS. Vitamin D supplementation may be an effective measure to reduce the risk of infection and improve the prognosis.

1 October 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
LQLing-Han Qin
Ling-Han Qin
JWJing Wu
Jing Wu
TLTing Liu
Ting Liu
YLYe Li
Ye Li
YSYu-Ru Shi
Yu-Ru Shi
YQYing-Jie Qi
Ying-Jie Qi
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral disease associated with substantial mortality. Renal dysfunction and coagulation abnormalities are closely related to disease severity. This study aimed to evaluate the prognostic significance of the blood urea nitrogen-to-fibrinogen ratio (BUN/FIB) in patients with SFTS. Methods: This single-center retrospective cohort study included adult patients with laboratory-confirmed SFTS admitted to the First Affiliated Hospital of the University of Science and Technology of China between June 2020 and June 2025. Admission BUN/FIB was calculated using BUN and fibrinogen values. Logistic regression, receiver operating characteristic (ROC) analysis, survival analysis, and paired-sample analysis were performed to evaluate the association between BUN/FIB and 30-day all-cause mortality. Results: Of the 475 patients, 378 (79.6%) survived and 97 (20.4%) died. Admission BUN/FIB levels were significantly higher in non-survivors than in survivors. Multivariable logistic regression identified older age, neurological signs, higher C-reactive protein, higher Ct-derived SFTSV RNA burden, and higher BUN/FIB (OR: 1.565; 95% CI: 1.348– 1.851; P< 0.001) as independently associated with 30-day mortality. BUN/FIB showed an apparent AUC of 0.835 (95% CI: 0.791– 0.880), with a cohort-derived cut-off of 3.312 mmol/g. This threshold showed a sensitivity of 78.4% and specificity of 78.0% but requires external validation. BUN/FIB showed higher apparent discrimination than conventional inflammatory indices and comparable apparent discrimination with Ct-derived SFTSV RNA burden. Higher BUN/FIB was associated with poorer survival. In paired analyses, BUN/FIB decreased among survivors and increased among non-survivors. Conclusion: Admission BUN/FIB was independently associated with 30-day mortality and showed favorable apparent discriminatory performance in this retrospective cohort. BUN/FIB may serve as a candidate adjunctive prognostic marker, but its optimal threshold, clinical utility, and generalizability require validation in prospective multicenter studies.